Why we Think It’s Important
This study explores the potential benefits of DehydraTECH™2.0 CBD, a novel CBD delivery system, and its effects on blood pressure, considering genetic factors, with implications for optimizing CBD formulations and enhancing its therapeutic potential in various disorders.
Cannabidiol (CBD) has been making waves in the world of natural remedies, and with good reason. This non-psychoactive cannabinoid has shown potential in treating various disorders. But what if there were a way to make CBD even more effective in addressing health issues? Enter the DehydraTECH™2.0 CBD, a groundbreaking capsule formulation designed to enhance CBD’s bioabsorption. In a recent double-blind study, researchers aimed to explore the effects of this novel CBD formulation on patients with hypertension, and the results are promising.
The Power of DehydraTECH™2.0 CBD
Before we dive into the study’s findings, let’s take a moment to understand what makes DehydraTECH™2.0 CBD unique. “DehydraTECH” is a technology developed by Lexaria Bioscience, a company focused on enhancing the delivery and absorption of bioactive compounds, including CBD. The technology is designed to improve the bioavailability of CBD and other compounds by making them more water-soluble and increasing their absorption in the human body. DehydraTECH™2.0 CBD is a patented capsule formulation developed to improve the way our bodies absorb CBD. The key to its success lies in enhancing the bioavailability of CBD, making it more efficient in providing potential health benefits.
Exploring CBD’s Impact on Hypertension
The study, titled “Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study,” aimed to investigate how CBD and DehydraTECH™2.0 CBD affect blood pressure, with a particular focus on genetic factors.
Researchers conducted a randomized, double-blind trial involving 12 females and 12 males, all of whom reported having hypertension. Participants were administered either placebo capsules or DehydraTECH™2.0 CBD capsules, each containing 300 mg of CBD. Blood pressure and heart rate were monitored over a 3-hour period, and blood and urine samples were collected for analysis.
A Closer Look at the Results
The results of the study revealed some intriguing findings. In the first 20 minutes following the dose, DehydraTECH™2.0 CBD led to a more significant reduction in diastolic blood pressure (the lower number in a blood pressure reading) and mean arterial pressure (MAP). This suggests that DehydraTECH™2.0 CBD may be more effective in lowering blood pressure, possibly due to its superior CBD bioavailability.
Genetic Factors in CBD Metabolism
Genetic factors play a crucial role in how individuals metabolize CBD. The study delved into the impact of polymorphisms in CYP P450 genes, which are responsible for the metabolism of various substances, including medications and cannabinoids. Some key findings related to these genes include:
- CYP2C923 Enzyme: Individuals with a “poor metabolizer” (PM) phenotype of this enzyme exhibited higher plasma CBD concentrations. This suggests that some individuals may experience different effects from CBD due to their genetic makeup.
- CYP2C192 and CYP2C1917: These two genetic variants were negatively associated with urinary CBD levels. In other words, individuals with specific variations in the CYP2C19 gene might not eliminate CBD from their bodies as efficiently as others.
- This study found that our genes can affect how our bodies process CBD. Some people with certain gene variations might have higher levels of CBD in their blood, while others may not clear CBD from their bodies as well, which could influence how CBD affects them.
Implications and Future Research
The study’s results open up exciting possibilities for the use of CBD in managing hypertension. However, the researchers emphasize the need for further investigation into the role of CYP P450 enzymes and the identification of metabolizer phenotypes. This information is crucial for optimizing CBD formulations and tailoring treatments to individual genetic profiles. All things considered, the study on DehydraTECH™2.0 CBD’s effects on hypertension offers a glimpse into the potential of CBD as a natural remedy. The enhanced bioavailability of this novel formulation could be a game-changer in the world of CBD therapy. With further research, we may unlock even more of CBD’s therapeutic potential and tailor treatments to suit the unique genetic profiles of individuals. As the medical community continues to explore the diverse applications of CBD, studies like these bring us one step closer to harnessing the full power of this natural cannabinoid in the pursuit of better health.
Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study. Pharmaceuticals (Basel). 2023 Apr 25;16(5):645. doi: 10.3390/ph16050645. PMID: 37242428; PMCID: PMC10223705. (Batinic A, Sutlović D, Kuret S, Matana A, Kumric M, Bozic J, Dujic Z.)